Synosia Therapeutics, Inc.

Biotie Therapies Corp. says it will be ready by the middle of the year to start a Phase III study of its adenosine A2a antagonist tozadenant in 882 Parkinson’s disease patients in North America and

Biotie Therapies Corp. says it will be ready by the middle of the year to start a Phase III study of its adenosine A2a antagonist tozadenant in 882 Parkinson’s disease patients in North America and

Versant Ventures’ Inception Sciences Inc. has been one of biotech’s most active asset-financing experiments. Now, to fuel international expansion, the firm wants to clone it in Canada, where the o

The past six months have seen something of a turnaround in the fortunes of the Finland-based biotech Biotie Therapies Corp. "We are now a company in transition, with cash, options and good news on